Summary

The cancer treatment drugs market is expected to grow at a strong CAGR of around 9% during the forecast period owing to the surge in the incidence of cancers, rising research and development activities for the development of novel cancer treatment drugs, and the development of a novel pipeline of cancer drugs. Moreover, the presence of various government and non-government organizations that aim to enhance awareness and promote research is also propelling market growth. For instance, Cancer Research Institute funded more than 120 clinical trials and invested around USD 474 million in research in 2020. In addition to this, the increasing funding from government organizations for cancer-related searches is also driving the cancer treatment drugs market. For instance, in June 2022, a group of Stanford scientists received funding of USD 13 million from Cancer Grand Challenges, a funding initiative by Cancer Research UK and the U.S. National Cancer Institute. This funding is awarded for the development of next-generation immunotherapies, the study of extrachromosomal DNA, and the investigation of early-stage malignancies.

Some of the major players operating in the market include AbbVie Inc.; F. Hoffmann-La Roche Ltd; Amgen Inc.; Pfizer Inc.; Bristol-Myers Squibb Company; Bayer AG; AstraZeneca; Sanofi; Merck & Co., Inc; and Johnson & Johnson Private Limited. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report
“Amongst therapy, the targeted therapy segment held a significant share of the market in 2021”
Based on therapy, the market is categorized into chemotherapy, immunotherapy, and targeted therapy. The targeted therapy segment held a significant share of the market in 2021 due to its small size, high efficiency, and specificity toward cancer cells. Moreover, researchers are also evaluating the role of targeted therapy in combination with other cancer-targeting regimens to enhance their efficacy. For instance, in June 2021, Exelixis announced clinical trial collaboration with Bristol Myers Squibb to evaluate the safety, tolerability and efficacy of XL092, Exelixis’ novel next-generation tyrosine kinase inhibitor (TKI), in combination with: nivolumab (OPDIVO®); nivolumab and ipilimumab (YERVOY®); and nivolumab and bempegaldesleukin.

“Amongst indication, the breast cancer category to grow with high CAGR during the forecast period”
By indication, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, and others. The breast cancer segment is anticipated to grow with significant CAGR during the forecast period due to a significant rise in the prevalence of breast cancer. According to Globocan, in 2020, about 2,261,419 new breast cancer cases were reported worldwide, contributing to about 11.7% of the total cancer cases. In addition, the increasing focus of market players on the development of novel breast cancer drugs is also driving the market growth during the forthcoming years. For instance, in July 2021, Arvinas Inc. and Pfizer Inc. collaborated to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. Such factors potentially drive the demand for the adoption of breast cancer therapy worldwide.

“Amongst distribution channel, the hospital pharmacies segment held a dominant share of the market in 2021”
Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies held a dominant share of the market in 2021. Several factors such as increase in the number of hospitalization due to various cancers, increasing prescriptions are driving the demand for cancer treatment drugs.

“APAC to grow with high CAGR during the forecast period”
APAC is expected to grow with the highest CAGR during the forecast period due to the surge in the prevalence of cancers, rising government initiatives for cancer awareness, and surge in patient assistance programs. Furthermore, the advancements in the treatment of cancers with latest product approvals and launches drives the growth of the market. For instance, in August 2022, AstraZeneca India has received a Drugs Controller General of India (DCGI) approval to market its drug Lynparza (Olaparib) as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2- negative high-risk early breast cancer. Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period.

Reasons to buy this report:
• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.

Customization Options:
The global cancer treatment drugs market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

ページTOPに戻る

Table of Contents

1 MARKET INTRODUCTION
1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1. Research Process of the Cancer Treatment Drugs Market
2.2. Research Methodology of the Cancer Treatment Drugs Market
2.3. Respondent Profile
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 IMPACT OF COVID-19 ON THE CANCER TREATMENT DRUGS MARKET
6 CANCER TREATMENT DRUGS MARKET REVENUE (USD BN), 2020-2028F
7 MARKET INSIGHTS BY DRUG CLASS
7.1. Cytotoxic Drugs
7.1.1. Alkylating Agents
7.1.2. Antimetabolites
7.1.3. Others
7.2. Targeted Drugs
7.2.1. Monoclonal Antibodies
7.2.2. Others
7.3. Hormonal Drugs
7.4. Others
8 MARKET INSIGHTS BY THERAPY
8.1. Chemotherapy
8.2. Targeted Therapy
8.3. Immunotherapy
9 MARKET INSIGHTS BY INDICATION
9.1. Lung Cancer
9.2. Breast Cancer
9.3. Colorectal Cancer
9.4. Prostate Cancer
9.5. Others
10 MARKET INSIGHTS BY DISTRIBUTION CHANNEL
10.1. Hospital Pharmacies
10.2. Retail Pharmacies
10.3. Online Pharmacies
11 MARKET INSIGHTS BY REGION
11.1. North America
11.1.1. U.S.
11.1.2. Canada
11.1.3. Rest of North America
11.2. Europe
11.2.1. Germany
11.2.2. U.K.
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3. Asia-Pacific
11.3.1. China
11.3.2. Japan
11.3.3. India
11.3.4. Rest of Asia-Pacific
11.4. Rest of World
12 CANCER TREATMENT DRUGS MARKET DYNAMICS
12.1. Market Drivers
12.2. Market Challenges
13 CANCER TREATMENT DRUGS MARKET OPPORTUNITIES
14 CANCER TREATMENT DRUGS MARKET TRENDS
15 DEMAND AND SUPPLY-SIDE ANALYSIS
15.1. Demand Side Analysis
15.2. Supply Side Analysis
16 VALUE CHAIN ANALYSIS
17 COMPETITIVE SCENARIO
17.1. Competitive Landscape
17.1.1. Porters Fiver Forces Analysis
18 COMPANY PROFILED
18.1. AbbVie Inc.
18.2. F. Hoffmann-La Roche Ltd
18.3. Amgen Inc.
18.4. Pfizer Inc.
18.5. Bristol-Myers Squibb Company
18.6. Bayer AG
18.7. AstraZeneca
18.8. Sanofi
18.9. Merck & Co., Inc.,
18.10. Johnson & Johnson Private Limited
19 DISCLAIMER